Position of the Transparency Council – Brukinsa (zanubrutinib)
At its meeting on 19 August 2024, the Transparency Council adopted position No. 85/2024 on the evaluation of the drug Brukinsa (zanubrutinib) within the framework of the drug program “Treatment of patients with B-cell lymphoma (ICD- 10: C82, C83, C85)”